Isolation and Characterization of Vaccine Candidate Genes Including CSP and MSP1 in Plasmodium yoelii
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Malaria is an infectious disease affecting humans, which is transmitted by the bite of Anopheles mosquitoes harboring sporozoites of parasitic protozoans belonging to the genus Plasmodium. Despite past achievements to control the protozoan disease, malaria still remains a significant health threat up to now. In this study, we cloned and characterized the full-unit Plasmodium yoelii genes encoding merozoite surface protein 1 (MSP1), circumsporozoite protein (CSP), and Duffy-binding protein (DBP), each of which can be applied for investigations to obtain potent protective vaccines in the rodent malaria model, due to their specific expression patterns during the parasite life cycle. Recombinant fragments corresponding to the middle and C-terminal regions of PyMSP1 and PyCSP, respectively, displayed strong reactivity against P. yoelii-infected mice sera. Specific native antigens invoking strong humoral immune response during the primary and secondary infections of P. yoelii were also abundantly detected in experimental ICR mice. The low or negligible parasitemia observed in the secondary infected mice was likely to result from the neutralizing action of the protective antibodies. Identification of these antigenic proteins might provide the necessary information and means to characterize additional vaccine candidate antigens, selected solely on their ability to produce the protective antibodies.
Abstract
Malaria is an infectious disease affecting humans, which is transmitted by the bite of Anopheles mosquitoes harboring sporozoites of parasitic protozoans belonging to the genus Plasmodium. Despite past achievements to control the protozoan disease, malaria still remains a significant health threat up to now. In this study, we cloned and characterized the full-unit Plasmodium yoelii genes encoding merozoite surface protein 1 (MSP1), circumsporozoite protein (CSP), and Duffy-binding protein (DBP), each of which can be applied for investigations to obtain potent protective vaccines in the rodent malaria model, due to their specific expression patterns during the parasite life cycle. Recombinant fragments corresponding to the middle and C-terminal regions of PyMSP1 and PyCSP, respectively, displayed strong reactivity against P. yoelii-infected mice sera. Specific native antigens invoking strong humoral immune response during the primary and secondary infections of P. yoelii were also abundantly detected in experimental ICR mice. The low or negligible parasitemia observed in the secondary infected mice was likely to result from the neutralizing action of the protective antibodies. Identification of these antigenic proteins might provide the necessary information and means to characterize additional vaccine candidate antigens, selected solely on their ability to produce the protective antibodies.
참고문헌 (45)
- White NJ, "Plasmodium knowlesi: the fifth human malaria parasite", Clin Infect Dis, 46, pp.172~173 (2008)
- Singh B, "Human infections and detection of Plasmodium knowlesi", Clin Microbiol Rev, 26, pp.165~184 (2013)
- World Malaria Report: 2016, "World Health Organization", World Health Organization, ~
- Cui L, "Antimalarial drug resistance: literature review and activities and findings of the ICEMR network", Am J Trop Med Hyg, 93(3 Suppl), pp.57~68 (2015)
- Richards JS, "The future for blood-stage vaccines against malaria", Immunol Cell Biol, 87, pp.377~390 (2009)
- Nunes JK, "Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward", Vaccine, 32, pp.5531~5539 (2014)
- Ouattara A, "Vaccines against malaria", Clin Infect Dis, 60, pp.930~936 (2015)
- Craig AG, "The role of animal models for research on severe malaria", PLoS Pathog, 8, pp.e1002401~ (2012)
- Otto TD, "A comprehensive evaluation of rodent malaria parasite genomes and gene expression", BMC Biol, 12, pp.86~ (2014)
- Lamb TJ, "Insights into the immunopathogenesis of malaria using mouse models", Expert Rev Mol Med, 8, pp.1~22 (2006)
- Kappe SH, "That was then but this is now : malaria research in the time of an eradication agenda", Science, 328, pp.862~866 (2010)
- Prudêncio M, "A toolbox to study liver stage malaria", Trends Parasitol, 27, pp.565~574 (2011)
- Ogun SA, "Targeted disruption of py235ebp-1: invasion of erythrocytes by Plasmodium yoelii using an alternative Py235 erythrocyte binding protein", PLoS Pathog, 7, pp.e1001288~ (2011)
- Burns JM Jr, "Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens", Infect Immun, 65, pp.3138~3145 (1997)
- Wykes MN, "Plasmodium yoelii can ablate vaccine-induced long-term protection in mice", J Immunol, 175, pp.2510~2516 (2005)
- Wipasa J, "Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine", Infect Immun, 77, pp.817~824 (2009)
- Hoffman EJ, "Susceptibility of CXB recombinant inbred mice to murine plasmodia", Infect Immun, 43, pp.981~985 (1984)
- Janse CJ, "High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei", Nat Protoc, 1, pp.346~356 (2006)
- Mount SM, "A catalogue of splice junction sequences", Nucleic Acids Res, 10, pp.459~472 (1982)
- Farley PJ, "Sequence of the gene encoding the N-terminal portion of the Plasmodium yoelii yoelii 17XL merozoite surface protein-1(MSP-1)", Gene, 151, pp.335~336 (1994)
- Jennings GJ, "The complete sequence of Plasmodium berghei merozoite surface protein-1 and its inter-and intra-species variability", Mol Biochem Parasitol, 93, pp.43~55 (1998)
- Pacheco MA, "Timing the origin of human malarias: the lemur puzzle", BMC Evol Biol, 11, pp.299~ (2011)
- de la Cruz VF, "Variation among circumsporozoite protein genes from rodent malarias", Mol Biochem Parasitol, 28, pp.31~38 (1988)
- Franke ED, "A subdominant CD8(+)cytotoxic T lymphocyte(CTL)epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture", Infect Immun, 68, pp.3403~3411 (2000)
- Cohen S, "Gamma-globulin and acquired immunity to human malaria", Nature, 192, pp.733~737 (1961)
- Fowkes FJ, "The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis", PLoS Med, 7, pp.e10000218~ (2010)
- Diggs CL, "The major merozoite surface protein as a malaria vaccine target", Parasitol Today, 9, pp.300~302 (1993)
- Holder AA, "The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria", Parasitology, 136, pp.1445~1456 (2009)
- Versiani FG, "N-terminal Plasmodium vivax merozoite surface protein-1, a potential subunit for malaria vivax vaccine", Clin Dev Immunol, 2013, pp.965841~ (2013)
- Curd RD, "The structure of Plasmodium yoelii merozoite surface protein 119, antibody specificity and implications for malaria vaccine design", Open Biol, 4, pp.130091~ (2014)
- Aikawa M, "The protective antigen of malarial sporozoites(Plasmodium berghei)is a differentiation antigen", J Immunol, 126, pp.2494~2495 (1981)
- Zavala F, "Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes", J Exp Med, 157, pp.1947~1957 (1983)
- Eichinger DJ, "Circumsporozoite protein of Plasmodium berghei : gene cloning and identification of the immunodominant epitopes", Mol Cell Biol, 6, pp.3965~3972 (1986)
- Espinosa DA, "Proteolytic cleavage of the Plasmodium falciparum circumsporozoite protein is a target of protective antibodies", J Infect Dis, 212, pp.1111~1119 (2015)
- David PH, "Parasite sequestration in Plasmodium falciparum malaria : spleen and antibody modulation of cytoadherence of infected erythrocytes", Proc Natl Acad Sci USA, 80, pp.5075~5079 (1983)
- Yamada S, "Potential therapeutic application of chondroitin sulfate", dermatan sulfate, 2008, pp.5, 289~301
- Smith JD, "Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes", Cell, 82, pp.101~110 (1995)
- Achur RN, "Characterization of proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans of the intervillous spaces that mediate the adherence of Plasmodium falciparum-infected erythrocytes to the placenta", J Biol Chem, 275, pp.40344~40356 (2000)
- Salanti A, "Selective up-regulation of a single distinctly structured var gene in chondroitin sulfate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria", Mol Microbiol, 49, pp.179~191 (2003)
- Clausen TM, "Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria", J Biol Chem, 287, pp.23332~23345 (2012)
- Brabin BJ, "An analysis of malaria in pregnancy in Africa", Bull World Health Organ, 61, pp.1005~1016 (1983)
- Hviid, L, "Of mice and women : rodent models of placental malaria", Trends Parasitol, 26, pp.412~419 (2010)
- Chia WN, "Novel approaches to identify protective malaria vaccine candidates", Front Microbiol, 5, pp.586~ (2014)
- Davies DH, "Large screen approaches to identify novel malaria vaccine candidates", Vaccine, 33, pp.7496~7505 (2015)
- França CT, "An antibody screen of a Plasmodium vivax antigen library identifies novel merozoite proteins associated with clinical protection", PLoS Negl Trop Dis, 10, pp.e0004639~ (2016)